Melanoma News and Research

Latest Melanoma News and Research

NeoGenomics' fourth-quarter revenue up 32%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter 2009 and fiscal year ended December 31, 2009.

25 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

AutoGenomics launches expanded test panel to detect 17 B-RAF mutations

AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.

24 Feb 2010

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Knowing the stage of a patient's melanoma is important when choosing the best course of treatment. When the cancer has progressed to the lymph nodes, a more aggressive treatment is needed. Examining an entire lymph node for cancer takes much effort and time; a new technique might help make the process more efficient.

24 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Delcath Systems, Inc., which is testing its proprietary treatment system for metastatic cancers to the liver, announced today that the U.S. Food and Drug Administration ("FDA") will allow the Company to initiate an Expanded Use – Intermediate Size Population protocol for the hepatic arterial infusion of melphalan with venous filtration via the Delcath PHP System™ for patients with ocular and cutaneous melanoma metastatic to the liver.

16 Feb 2010

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Today, Formatech, Inc. announced the issuance of U.S. patent 7,659,310, entitled “Methods of Enhancing Solubility of Agents” which covers novel formulation methods to enhance the solubility of certain hydrophobic compounds.

12 Feb 2010

EMEA grants Genta's request for SME designation

Genta Incorporated announced that it has received $2.8 million in non-dilutive cash proceeds from the sale of net operating tax losses and research tax credits generated in prior tax years as part of the Technology Business Tax Certificate Program sponsored by the New Jersey Economic Development Authority (NJEDA), pursuant to the rules, regulations and stipulations set forth by the program.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals Corp. today announced that preclinical results presented at the “Bridging the Gap 2010” Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shock protein 90 (Hsp90), inhibits the Wilms’ tumor 1 (WT1) protein, a key transcription factor that drives disease progression in acute myeloid leukemia (AML) as well as certain other leukemias. STA-9090 is currently enrolling patients in two clinical trials in AML and other hematologic cancers.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced

Delcath Systems, Inc., a medical technology company testing its proprietary treatment system for metastatic cancers to the liver, announced today that sufficient events have been reached to allow data analysis to begin on its Phase III trial. The trial uses the drug melphalan to treat patients with metastatic melanoma in the liver.

4 Feb 2010

Dundee Centre to help set the pace for national and international progress in cancer research

Dundee today (Thursday) becomes Scotland's first link in a unique chain of Cancer Research UK Centres that are being launched across the UK. The launch of the Dundee Centre coincides with World Cancer Day.

4 Feb 2010

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

3 Feb 2010

Study identifies disparities in sun protection behavior

Only about 31 percent of African-American adults engage in at least one form of sun protection behavior such as wearing a hat, while 63 percent never use sunscreen, according to a new study.

3 Feb 2010

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled data from all trials, less than one percent of treated patients developed product-specific antibodies. None of the antibodies neutralized native coagulation proteins.

2 Feb 2010

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

IsoRay, Inc. announced today that it has successfully shipped the first set of Cesium-131 brachytherapy seeds to a Canadian customer for the purpose of furthering research and development of Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada for the treatment of low-risk prostate cancers and has been cleared by the US FDA for treatment of a wide variety of malignant disease (e.g. prostate, head and neck, brain, breast, lung, eye, etc.).

28 Jan 2010

Melanoma News and Research

Latest Melanoma News and Research

NeoGenomics' fourth-quarter revenue up 32%

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

EpiCept provides business update and fourth-quarter financial highlights

AutoGenomics launches expanded test panel to detect 17 B-RAF mutations

Researchers study how laser-induced ultrasound could help identify the stage of melanoma

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

Antigenics announces fourth-quarter and full-year 2009 financial results

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

EMEA grants Genta's request for SME designation

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Genta commences Phase 2 trial of tesetaxel on first subject

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced

Dundee Centre to help set the pace for national and international progress in cancer research

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

Study identifies disparities in sun protection behavior

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

IsoRay ships first set of Cesium-131 brachytherapy seeds to Canada

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Melanoma News and Research

Latest Melanoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in